Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma
Roger Stupp(Northwestern University), Michael Weller(University Hospital of Zurich), Mirjam Hermisson(University of Lausanne), Roland Goldbrunner(University of Cologne), Annie-Claire Diserens(University of Lausanne), Matthias Simon(University of Bonn), Stefan Krueger(University of Lausanne), Adrian F. Ochsenbein(University of Bern), Monika E. Hegi(University Hospital of Lausanne), Torsten Pietsch(University Hospital Bonn), Martin Picard(Columbia University Irving Medical Center), Uwe Schlegel(Defence Research and Development Organisation), Gerhard G. Grabenbauer(Klinikum Coburg), Bart Neyns(Universitair Ziekenhuis Brussel), Alessia Pica(University of Lausanne), Pierre-Yves Dietrich(University of Lausanne), Christine Hicking(Merck KGaA, Darmstadt (Germany)), Joerg-Christian Tonn(LMU Klinikum), Paul M. Clément(Universitair Ziekenhuis Leuven)
Cited by 445
Related Papers
<i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Glioblastoma
|New England Journal of Medicine|2005|7.2k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
|Nature Reviews Clinical Oncology|2020|1.9k